ANAB ANAPTYSBIO, INC

BEARISH Impact: 5/10 144
Horizon days Filed Jun 1, 2026 Processed 13d 10h ago SEC 0001950047-26-005454
Form 144 — notice of proposed sale of securities
Latest settled — T+1d
ANAB ▼ -0.04% at T+1d
SHORT call ✓ call won +0.04% · α vs SPY -0.68% · entry $51.26 → $51.24
Next anchor: T+5d due 7d ago
Last close $56.07 (close Jun 12) · -9.38% from $51.26 entry (call sign-flipped)
Entry anchored
Jun 1, 2026
via day open
T+1d
-0.04%
call +0.04% · α -0.68%
$51.24
settled 13d ago
T+5d
call — · α —
due 7d ago
T+20d
call — · α —
in 15d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 1, 2026, indicating intent to sell 7,691 shares of common stock valued at approximately $404,340. This follows a series of recent open-market sales by Mulroy totaling over 80,000 shares in the prior two weeks, suggesting a pattern of insider monetization.

Actionable Insight

The officer has been a consistent seller over the past two weeks, disposing of over 80,000 shares. While the Form 144 amount is modest relative to market cap, the pattern of sustained selling by an insider warrants monitoring for any upcoming negative catalyst or earnings miss.

Key Facts

  • Officer Dennis Mulroy filed Form 144 to sell 7,691 shares valued at ~$404,340.
  • Mulroy has sold 80,731 shares in open-market transactions from May 15 to May 29, 2026, totaling ~$4.8M.
  • The proposed sale is via Morgan Stanley Smith Barney LLC.
  • Shares were acquired via stock option exercise on June 1, 2026.
  • AnaptysBio has a market cap of $1.6B and 89% analyst bullish consensus.

Financial Impact

Proposed sale of $404K; cumulative recent sales by officer exceed $5M.

insider selling volume

Risk Factors

  • Insider selling ahead of potential negative news or clinical data.
  • Further unannounced sales may pressure the stock.
  • Pattern may signal lack of confidence in near-term prospects despite bullish analyst consensus.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (18 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005454
Document: 0001950047-26-005454-index.html0001950047-26-005454
Document: 0001950047-26-005454.txt0001950047-26-005454
17 reports for ANAB
Performance horizon
86% Hit rate 6 of 7 directional calls best @ T+60▲ +41.26%Mar 3, 2026
Filters
Rows
Reports for ANAB — sortable, filterable
Type Now
Jun 11, 2026
3d ago
144
BEARISH ★ 6/10
$54.24 awaiting T+1awaiting T+1$56.07 (−3.38%)
Jun 10, 2026
4d ago
144
BEARISH ★ 5/10
$51.96 awaiting T+1awaiting T+1$56.07 (−7.91%)
Jun 8, 2026
6d ago
144
BEARISH ★ 5/10
$51.38 awaiting T+1awaiting T+1$56.07 (−9.14%)
Jun 5, 2026
9d ago
144
BEARISH ★ 5/10
$50.58 awaiting T+1awaiting T+1$56.07 (−10.85%)
Jun 5, 2026
9d ago
144
BEARISH ★ 5/10
$51.33 awaiting T+1awaiting T+1$56.07 (−9.23%)
Jun 3, 2026
11d ago
144
BEARISH ★ 5/10
$51.67 $50.37▲ +2.52%▼ −0.08%$56.07 (−8.52%)
Jun 1, 2026
13d ago
144
BEARISH ★ 5/10
$51.26 $51.24▲ +0.04%▼ −0.68%$56.07 (−9.38%)
May 29, 2026
16d ago
8-K
NEUTRAL ★ 2/10
$53.14 $51.26▼ −3.54%▼ −3.69%$56.07 (+5.51%)
May 28, 2026
17d ago
144
NEUTRAL ★ 3/10
$55.67 $53.14▼ −4.54%▼ −4.80%$56.07 (+0.72%)
May 27, 2026
18d ago
144
BEARISH ★ 6/10
$57.02 $55.67▲ +2.37%▲ +2.61%$56.07 (+1.67%)
Showing 10 of 17

US Market Status

Market Closed — Opens in 5h 6m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access